# NG-TEST Aci

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ng-test-aci
Canonical HTML page: https://gethealthbrief.com/entity/ng-test-aci

## Recent coverage (1 stories)

### NG Biotech and Hardy Diagnostics Secure FDA Breakthrough for AMR Assays
2026-02-19 11:10:27 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

NG Biotech and Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic assays targeting multidrug-resistant pathogens. The NG-TEST Candida auris and NG-TEST Aci assays provide rapid, point-of-care identification of high-priority healthcare-associated infections.
Full story: https://gethealthbrief.com/story/ng-biotech-hardy-diagnostics-fda-breakthrough-amr

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.